Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prothena Corp Public (PRTA) Cash & Equivalents (2016 - 2025)

Prothena Corp Public has reported Cash & Equivalents over the past 14 years, most recently at $307.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $307.5 million for Q4 2025, down 34.77% from a year ago — trailing twelve months through Dec 2025 was $307.5 million (down 34.77% YoY), and the annual figure for FY2025 was $307.5 million, down 34.77%.
  • Cash & Equivalents for Q4 2025 was $307.5 million at Prothena Corp Public, down from $330.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PRTA hit a ceiling of $710.4 million in Q4 2022 and a floor of $307.5 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $531.1 million (2022), compared with a mean of $517.2 million.
  • Biggest five-year swings in Cash & Equivalents: surged 96.05% in 2021 and later plummeted 36.29% in 2025.
  • Prothena Corp Public's Cash & Equivalents stood at $579.1 million in 2021, then rose by 22.68% to $710.4 million in 2022, then decreased by 12.89% to $618.8 million in 2023, then decreased by 23.83% to $471.4 million in 2024, then crashed by 34.77% to $307.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $307.5 million (Q4 2025), $330.8 million (Q3 2025), and $371.4 million (Q2 2025) per Business Quant data.